Skip to content
Nonprofiteer
← TARGET ALS FOUNDATION INC

Form 990 for tax year 2025

Filed by TARGET ALS FOUNDATION INC.

Totals

Total revenue
$33,261,985
Total expenses
$25,618,714
Contributions and grants received
$29,724,385
Grants paid
$18,765,868
Program service revenue
$0
Investment income
$3,535,375
Other revenue
$2,225
Total assets, end of year
$136,912,637
Total liabilities, end of year
$1,853,620
Net assets or fund balances, end of year
$135,059,017
Program services expenses (Part IX)
$21,006,355
Management and general expenses
$2,853,592
Fundraising expenses
$1,758,767
Program service expenses (Part III)
$21,006,355

Program services were 82.0% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1f · All other contributions, gifts and grants

    $29,724,385

  • 1g · Noncash contributions included above

    $6,226,324

  • 3 · Investment income

    total $3,253,081 · excluded $3,253,081

  • 7a · Gross sales of assets other than inventory

    securities $15,396,004

  • 7b · Less cost or other basis and sales expenses

    securities $15,113,710

  • 7c · Gain or loss

    securities $282,294

  • 7d · Net gain or loss

    total $282,294 · excluded $282,294

  • 11a · Other revenue: OTHER INCOME

    total $2,225 · excluded $2,225

  • 11e · Other revenue, total

    $2,225

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $13,067,691 · program services $13,067,691

  • 3 · Grants to foreign organizations and individuals

    total $5,698,177 · program services $5,698,177

  • 5 · Compensation of officers, directors and key employees

    total $970,997 · program services $350,438 · management and general $329,004 · fundraising $291,555

  • 7 · Other salaries and wages

    total $2,080,679 · program services $425,646 · management and general $1,249,279 · fundraising $405,754

  • 8 · Pension plan contributions

    total $104,034 · program services $21,282 · management and general $62,464 · fundraising $20,288

  • 9 · Other employee benefits

    total $499,114 · program services $77,981 · management and general $326,462 · fundraising $94,671

  • 10 · Payroll taxes

    total $200,843 · program services $48,967 · management and general $104,303 · fundraising $47,573

  • 11b · Fees: legal

    total $32,006 · management and general $32,006

  • 11c · Fees: accounting

    total $91,859 · management and general $91,859

  • 11f · Fees: investment management

    total $176,591 · management and general $176,591

  • 11g · Fees: other

    total $258,252 · management and general $194,765 · fundraising $63,487

  • 12 · Advertising and promotion

    total $802,482 · fundraising $802,482

  • 13 · Office expenses

    total $99,032 · program services $6,004 · management and general $76,414 · fundraising $16,614

  • 16 · Occupancy

    total $143,162 · management and general $143,162

  • 17 · Travel

    total $94,181 · program services $20,974 · management and general $58,708 · fundraising $14,499

  • 19 · Conferences, conventions and meetings

    total $1,299,614 · program services $1,289,195 · management and general $8,575 · fundraising $1,844

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $2,137,916 · end of year $3,278,742

  • 2 · Savings and temporary cash investments

    beginning of year $8,351,865 · end of year $4,679,056

  • 3 · Pledges and grants receivable

    beginning of year $49,311,907 · end of year $45,694,945

  • 7 · Other notes and loans receivable

    beginning of year $250,000

  • 9 · Prepaid expenses and deferred charges

    beginning of year $76,751 · end of year $75,597

  • 12 · Investments: other securities

    beginning of year $68,783,323 · end of year $83,184,297

  • 17 · Accounts payable and accrued expenses

    beginning of year $33,343 · end of year $25,316

  • 18 · Grants payable

    beginning of year $4,318,332 · end of year $1,828,304

  • 27 · Net assets without donor restrictions

    beginning of year $81,346,621 · end of year $91,694,347

  • 28 · Net assets with donor restrictions

    beginning of year $43,213,466 · end of year $43,364,670

Mission and programs · 2025

Mission

OUR MISSION IS TO BREAK DOWN BARRIERS TO ALS RESEARCH TO FIND EFFECTIVE TREATMENTS. BY UNITING ACADEMIA, THE PHARMA AND BIOTECH INDUSTRY, GOVERNMENT, VENTURE CAPITAL, RELATED NONPROFITS, AND THE ALS COMMUNITY, WE AIM TO OVERCOME THE CHALLENGES THAT HAVE LONG HINDERED PROGRESS, BRINGING HOPE AND TANGIBLE ADVANCEMENTS TO THOSE AFFECTED BY THIS DEVASTATING DISEASE.

  • RESEARCH WE FUND:TARGET ALS IS THE LARGEST AND MOST IMPACTFUL PRIVATE FUNDER OF ALS RESEARCH WORLDWIDE. THANKS TO THE GENEROUS TRUST PLACED IN US BY OUR DONORS, WE CAN DIRECT RESOURCES TO THE MOST PROMISING IDEAS AND EMERGING SCIENTIFIC LEADERS ACROSS THE GLOBE. OUR FUNDED PROJECTS HAVE A HIGH SUCCESS RATE, DELIVERING MEANINGFUL RESULTS TO ADVANCE IDEAS FROM EARLY TO LATE STAGE RESEARCH. IN 2025, WE CONTINUED TO EXPAND FUNDING OPPORTUNITIES, DRIVING NEARLY $12M INTO INNOVATION ACROSS 151 GRANTS IN THREE CRITICAL AREAS:UNDERSTANDING ALS BIOLOGY: ADVANCING INSIGHTS INTO THE ROOT CAUSES OF DISEASE TO IDENTIFY NEW DRUG TARGETS.ACCELERATING DRUG DISCOVERY: SUPPORTING PROOF-OF-CONCEPT STUDIES THAT PAVE THE WAY TOWARD CLINICAL TRIALS.DEVELOPING BIOMARKERS: ENABLING EARLIER DIAGNOSIS, IDENTIFYING ALS SUBTYPES, AND MONITORING DISEASE PROGRESSION WITH PRECISIONEVERY GRANT THAT TARGET ALS FUNDS IS TIED TO A DELIBERATE STRATEGY AND A LONG-RANGE VISION FOR THE FIELD, ENSURING THAT PROMISING IDEAS MOVE THROUGH THE FULL RESEARCH PATHWAY: UNCOVERING DISEASE BIOLOGY, IDENTIFYING AND REFINING NEW THERAPEUTIC TARGETS OR BIOMARKERS, VALIDATING THEM IN RIGOROUS MODELS, GENERATING TRANSLATIONAL DATA, AND PREPARING THE STRONGEST CANDIDATES FOR CLINICAL DEVELOPMENT. OUR FUNDING ALLOCATION REFLECTS WHERE THE STRONGEST IDEAS EMERGE. THE DISTRIBUTION OF OUR FUNDING ISN'T SET BY QUOTAS OR PERCENTAGES. IT'S SHAPED BY WHERE THE MOST COMPELLING SCIENCE IS HAPPENING. EACH YEAR, WE INVEST IN THE PROPOSALS WITH THE CLEAREST BIOLOGICAL RATIONALE, THE STRONGEST EVIDENCE, AND THE GREATEST POTENTIAL TO ADVANCE THE FIELD. RESEARCH WE ENABLE:TARGET ALS CONTINUES TO BREAK DOWN BARRIERS TO PROGRESS BY OFFERING NO-STRINGS-ATTACHED ACCESS TO CRITICAL TOOLS AND RESOURCES THROUGH OUR RESEARCH CORES. THESE SHARED RESOURCES ADDRESS LONGSTANDING CHALLENGES IN ALS RESEARCH THAT HAVE HISTORICALLY SLOWED DISCOVERY: LIMITED ACCESS, HIGH COSTS, AND LACK OF STANDARDIZATION. THE RESEARCH CORES ACCELERATE DRUG DISCOVERY AND BIOMARKER DEVELOPMENT WHILE FOSTERING COLLABORATION ACROSS THE GLOBAL ALS COMMUNITY. IN 2025, TARGET ALS INVESTED OVER $8M TO EMPOWER SCIENTISTS WITH THE MATERIALS, DATA, AND INFRASTRUCTURE THEY NEED TO DRIVE PROGRESS FROM THE BENCH TO THE CLINIC. FROM OUR POSTMORTEM TISSUE CORE TO THE LONGITUDINAL BIOFLUIDS CORE POWERED BY OUR GLOBAL NATURAL HISTORY STUDY (GNHS) AND OPEN-ACCESS DATA ENGINE, TARGET ALS PROVIDES RESEARCHERS WORLDWIDE WITH STATE-OF-THE-ART BIOSAMPLES, DATASETS, ANTIBODIES, AND MORE, WITH NO REACHTHROUGH ON INTELLECTUAL PROPERTY (IP). THESE TOOLS ARE AVAILABLE TO BOTH ACADEMIA AND INDUSTRY, ENSURING THAT SCIENTIFIC BREAKTHROUGHS CAN MOVE SWIFTLY AND COLLABORATIVELY TOWARD THERAPIES FOR PEOPLE LIVING WITH ALS. TO DATE, MORE THAN 1,750 PROJECTS HAVE RELIED ON THESE RESOURCES, SPANNING BASIC BIOLOGY, TARGET VALIDATION, BIOMARKER DISCOVERY, AND THERAPEUTIC DEVELOPMENT. AND THE MOMENTUM IS ONLY GROWING: OVER 500 RESEARCHERS HAVE ACCESSED OUR DATA ENGINE, WHILE GLOBAL CONSORTIA OF PREEMINENT SCIENTISTS ARE WORKING TOGETHER WITH TARGET ALS FUNDS TO SHARE DATA, REPLICATE FINDINGS, AND AMPLIFY IMPACT.RESEARCH WE CONDUCT:ALS IS A DISEASE THAT AFFECTS PEOPLE OF EVERY RACE AND ETHNICITY AROUND THE WORLD. HOWEVER, CLINICAL TRIALS ENROLL PRIMARILY PEOPLE OF WHITE, EUROPEAN DESCENT RESULTING IN A BIASED, INCOMPLETE VIEW OF DISEASE BIOLOGY ACROSS THE ALS GLOBAL POPULATION. THE ALS GLOBAL RESEARCH INITIATIVE (AGRI) IS THE ONLY COMPREHENSIVE, GLOBAL RESEARCH EFFORT THAT BRINGS TOGETHER TWO COMPLEMENTARY CLINICAL STUDIES DESIGNED TO UNCOVER THE CAUSES OF ALS AND IDENTIFY NEW BIOMARKERS THAT CAN DIAGNOSE THE DISEASE EARLIER, TRACK ITS PROGRESSION, AND PREDICT OUTCOMES. THESE STUDIES PROVIDE RESEARCHERS UNPRECEDENTED ACCESS TO PATIENT DATA AND BIOSAMPLES WORLDWIDE, RAPIDLY ACCELERATING NEW DISCOVERIES AND DRIVING PROGRESS TOWARD MORE EFFECTIVE THERAPIES. ULTIMATELY, INCLUSIVE RESEARCH STRENGTHENS SCIENTIFIC VALIDITY, IMPROVES PATIENT OUTCOMES, AND HELPS ENSURE THAT BREAKTHROUGHS BENEFIT EVERYONE, NOT JUST A SUBSET OF THE POPULATION. THROUGHOUT THE YEAR, WE INVESTED OVER $1.5M, WHICH FUELED AGRI'S BOLD GOAL: BRING THE WORLD TOGETHER TO TACKLE ALS FROM EVERY ANGLE. THROUGH OUR GLOBAL NATURAL HISTORY STUDY (GNHS) AND COMMUNITYBASED POP-UP CLINICS, WE'RE MAKING ALS RESEARCH MORE INCLUSIVE, MORE IMMEDIATE, AND MORE COLLABORATIVE THAN EVER BEFORE.

    Expenses $21,006,355 · Grants $18,765,868

As filed on the 2025 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • DANIEL L DOCTOROFF

    BOARD CHAIR

    Total calculated
    $0
    Hours/week
    1

  • JOHN DUNLOP

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • BRAD S KARP

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • ZACH W HALL

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • STORY LANDIS

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • SARAH SHEIKH

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • ALISA DOCTOROFF

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • ALLISON JAFFIN

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • ANDY BERNDT

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • CHRIS HERNDERSON

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • RICHARD HARGREAVES

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • CAROL HO

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • STACY WENINGER

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • ERIC DANE

    BOARD MEMBER (AS OF 12/25)

    Total calculated
    $0
    Hours/week
    1

  • MANISH RAISINGHANI

    PRESIDENT

    Total calculated
    $445,255
    From this org
    $404,414
    From related orgs
    $0
    Other
    $40,841
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $404,414
    Bonus
    $0
    Other
    $0
    Deferred
    $20,221
    Nontaxable benefits
    $20,620
    Filer's total
    $445,255

  • KENNETH DEVANEY

    CHIEF OPERATING OFFICER

    Total calculated
    $329,004
    From this org
    $293,699
    From related orgs
    $0
    Other
    $35,305
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $293,699
    Bonus
    $0
    Other
    $0
    Deferred
    $14,685
    Nontaxable benefits
    $20,620
    Filer's total
    $329,004

  • JESSICA CHAPMAN

    CHIEF DEVELOPMENT OFFICER

    Total calculated
    $309,452
    From this org
    $240,468
    From related orgs
    $0
    Other
    $68,984
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $240,468
    Bonus
    $0
    Other
    $0
    Deferred
    $14,995
    Nontaxable benefits
    $53,989
    Filer's total
    $309,452

  • AMY EASTON

    VICE PRESIDENT, RESEARCH GROUPS

    Total calculated
    $368,882
    From this org
    $299,898
    From related orgs
    $0
    Other
    $68,984
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $299,898
    Bonus
    $0
    Other
    $0
    Deferred
    $14,995
    Nontaxable benefits
    $53,989
    Filer's total
    $368,882

  • YULIYA RZAD

    CHIEF GRANTS OFFICER

    Total calculated
    $249,759
    From this org
    $206,142
    From related orgs
    $0
    Other
    $43,617
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $206,142
    Bonus
    $0
    Other
    $0
    Deferred
    $10,307
    Nontaxable benefits
    $33,310
    Filer's total
    $249,759

  • CHRISTINE PROUTY ARANYOS

    DIRECTOR OF PHILANTHROPY

    Total calculated
    $227,493
    From this org
    $165,242
    From related orgs
    $0
    Other
    $62,251
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $165,242
    Bonus
    $0
    Other
    $0
    Deferred
    $8,262
    Nontaxable benefits
    $53,989
    Filer's total
    $227,493

  • LAURA DUGOM

    ASSOCIATE DIRECTOR CLINICAL RESEARCH

    Total calculated
    $197,920
    From this org
    $168,857
    From related orgs
    $0
    Other
    $29,063
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $168,857
    Bonus
    $0
    Other
    $0
    Deferred
    $8,443
    Nontaxable benefits
    $20,620
    Filer's total
    $197,920

  • STEPHANIE ISHOO

    DIRECTOR OF MARKETING & COMMUNICATIONS

    Total calculated
    $192,869
    From this org
    $165,555
    From related orgs
    $0
    Other
    $27,314
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $165,555
    Bonus
    $0
    Other
    $0
    Deferred
    $8,278
    Nontaxable benefits
    $19,036
    Filer's total
    $192,869

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Independent compensation consultant
  • 3 · Compensation survey or study
  • 3 · Approval by the board or compensation committee

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 7 · Other non-fixed payments
  • 8 · Paid under the initial-contract exception

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

The 10 largest by cash amount. The API serves every itemized grant.

Provenance

Return type
form_990
Tax year
2025
Filed
17 April 2026
IRS schema version
2025v4.1
Source object
202611109349300966

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.